secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prestige Consumer Healthcare Inc. (PBH)
CIK:        0001295947
Form:       8-K
Filed at:   2021-07-01T23:59:59+00:00
Accession:  0001104659-21-088218
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prestige completes $230M acquisition of TheraTears from Akorn, refinances term loan.
--------------------------------------------------------------------------------

- Acquired TheraTears and other OTC brands from Akorn Operating Company for $230M cash, closed July 1, 2021.
- Deal expected to add ~$60M annual revenue, ~$0.10 EPS, ~$13M operating cash flow.
- Expected annual EBITDA ~$20M, tax benefits ~$30M; transaction valued at <10x pro-forma EBITDA.
- Financed via cash, ABL revolver, and new $600M Term B-5 Loans (LIBOR+2%, floor 0.5%, maturity 2028).
- Announced Q1 fiscal 2022 earnings release scheduled for August 5, 2021, conference call at 8:30 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1295947/000110465921088218/0001104659-21-088218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1295947/000110465921088218/tm2121213d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-088218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer